Year Ended March 31,

2016

($)

Year Ended March 31,

2015

($)

Balance due from Pharma and NDM at beginning of period

192,517

-

Amounts advanced to Pharma

58,197

567,633

Amounts received from Pharma

(228,361

)

(7,692

)

Reduction in prepayments to Pharma for clinical trials

(247,596

)

(257,441

)

Amounts invoiced by Pharma to DDL and TCL

(331,714

)

(106,193

)

Amounts invoiced by DDL to Pharma

16,307

-

Expenses paid by Pharma on behalf of DDL and TCL

-

134

Intellectual property costs paid by Pharma on behalf of DDL and TCL

-

(946

)

Sale of fixed and intangible assets to Pharma and NDM

17,775

-

Foreign exchange differences

28,763

(2,988

)

Net balance due to Pharma and NDM at end of the period

(494,112

)

192,517